Clinical Trial Update: Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study evaluating adding GSK2190915 to mid-dose inhaled corticosteroid/long-acting beta agonist therapy in asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK2190915

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED